- Home
- AGIO
as of 12-11-2025 1:12pm EST
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 1.6B | IPO Year: | 2013 |
| Target Price: | $32.13 | AVG Volume (30 days): | 2.5M |
| Analyst Decision: | Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -6.96 | EPS Growth: | N/A |
| 52 Week Low/High: | $22.24 - $51.27 | Next Earning Date: | 10-30-2025 |
| Revenue: | $44,791,000 | Revenue Growth: | 36.26% |
| Revenue Growth (this year): | 28.75% | Revenue Growth (next year): | 139.45% |
AI-Powered AGIO Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Agios Pharmaceuticals Inc. (AGIO)
Director
Avg Cost/Share
$43.84
Shares
200
Total Value
$8,768.00
Owned After
17,603
SEC Form 4
Chief Medical Officer
Avg Cost/Share
$43.78
Shares
2,454
Total Value
$107,436.12
Owned After
61,727
SEC Form 4
Chief Medical Officer
Avg Cost/Share
$43.81
Shares
200
Total Value
$8,762.00
Owned After
61,727
SEC Form 4
Chief Medical Officer
Avg Cost/Share
$43.92
Shares
3,302
Total Value
$145,023.84
Owned After
61,727
SEC Form 4
Director
Avg Cost/Share
$41.00
Shares
200
Total Value
$8,200.00
Owned After
17,603
SEC Form 4
Director
Avg Cost/Share
$40.00
Shares
200
Total Value
$8,000.00
Owned After
17,603
SEC Form 4
Chief Financial Officer
Avg Cost/Share
$36.77
Shares
3,651
Total Value
$134,247.27
Owned After
33,870
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Scadden David | AGIO | Director | Nov 12, 2025 | Sell | $43.84 | 200 | $8,768.00 | 17,603 | |
| Gheuens Sarah | AGIO | Chief Medical Officer | Nov 11, 2025 | Sell | $43.78 | 2,454 | $107,436.12 | 61,727 | |
| Gheuens Sarah | AGIO | Chief Medical Officer | Oct 30, 2025 | Sell | $43.81 | 200 | $8,762.00 | 61,727 | |
| Gheuens Sarah | AGIO | Chief Medical Officer | Oct 27, 2025 | Sell | $43.92 | 3,302 | $145,023.84 | 61,727 | |
| Scadden David | AGIO | Director | Oct 8, 2025 | Sell | $41.00 | 200 | $8,200.00 | 17,603 | |
| Scadden David | AGIO | Director | Sep 30, 2025 | Sell | $40.00 | 200 | $8,000.00 | 17,603 | |
| Jones Cecilia | AGIO | Chief Financial Officer | Sep 26, 2025 | Sell | $36.77 | 3,651 | $134,247.27 | 33,870 |
Compare AGIO vs Leading Stocks
See how AGIO stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "AGIO Agios Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.